Unraveling Patient‐Preferred Health and Treatment Outcomes in Early Rheumatoid Arthritis: A Longitudinal Qualitative Study

Elst, Kristien Van der; Meyfroidt, Sabrina; Cock, Diederik De; Groef, An De; Binnard, E.; Moons, Philip; Verschueren, Patrick; Westhovens, René

doi:10.1002/acr.22824

Cited by 52 publications

(51 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, we showed a lower cumulative disease activity and faster treatment response on MTX with GCs over the first year, which seems more in accordance with patients' preferences 32. Moreover, the comparable safety profile in both low-risk arms provides important new evidence that GC remission induction is relatively safe in patients with so-called mild ERA.…”

Section: Discussionsupporting

confidence: 79%

Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial

Verschueren¹,

Cock

Corluy³

et al. 2016

Ann Rheum Dis

Self Cite

101

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 79%

Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial

Verschueren¹,

Cock

Corluy³

et al. 2016

Ann Rheum Dis

Self Cite

101

View full text Add to dashboard Cite

show abstract

“…In a qualitative study evaluating early RA patients’ preferred health and treatment outcomes, van der Elst et al [44] confirmed the importance of attaining ‘normality’. Patients interviewed twice over 1 year after initiating treatment emphasized the importance of returning to normal in terms of disease control, improved pain and physical function, mental well being, and participation at work, home, and leisure.…”

Section: Additional Recent Publications Incorporating the Patient Permentioning

confidence: 99%

Incorporating the patient's perspective in outcomes research

Hsiao

Fraenkel

2017

Current Opinion in Rheumatology

View full text Add to dashboard Cite

Purpose of review Incorporation of the patients’ perspective in clinical research is critical to ensure that outcomes measured reflect those, which matter most to patients. This review summarizes recent efforts to include the patients’ perspective in the development of outcome measures and the importance of encouraging patient participation in decision-making and self-management. Recent findings Since the inclusion of fatigue as a patient-endorsed core outcome measure in rheumatoid arthritis (RA) trials, OMERACT has been instrumental in advocating for patient involvement in the development of core domains and instruments; current endeavors include cultivating an understanding of remission through the eyes of patients and gaining a sense of how to measure features of pain and ‘stiffness’ deemed as important to patients. The concept of remission was further explored in RA patients, highlighting a common goal of returning to normality; additionally, various tools have been developed to assess for unmet needs in rheumatology patients. Advances have also been made in the development and revision of patient-centered core measures in rheumatologic diagnoses outside of RA. Summary Incorporating the patients’ perspective is now considered an essential feature in outcomes research. Future research should focus on how best to involve patients in specific research activities.

show abstract

“…A whole treatment movement has grown out of this approach – “Treat To Target” – in which treatment is increased until patients achieve the defined target 7 . The growing focus on early treatment of inflammatory arthritis has been associated with an increased emphasis by patients on being able to return to normality as soon as possible 8 .…”

Section: Present Uncertaintiesmentioning

confidence: 99%

Developing new therapeutic approaches for rheumatoid arthritis: the continuing challenges of clinical assessments

Scott

2016

F1000Res

View full text Add to dashboard Cite

The management of rheumatoid arthritis has changed dramatically over the last three decades. Improvements in clinical assessment have been a key driver of these changes. However, in the last five years, three areas of unresolved uncertainty have dominated specialist thinking in the field. These challenges comprise identifying the optimal management target, determining how best to reach this target by using intensive treatments, and individualising management because not all patients need or respond to identical treatments. The key problem that links each of these areas is balancing different types of evidence and is most readily appreciated in relation to treatment intensity. Giving more intensive therapy improves outcomes but also increases risks and, with biologic treatments, substantially increases drug costs. Specialists and healthcare funders need to agree on how best to rationalise optimal care for patients with what is most effective and safe and what is affordable.

show abstract

Unraveling Patient‐Preferred Health and Treatment Outcomes in Early Rheumatoid Arthritis: A Longitudinal Qualitative Study

Abstract: From a patient perspective, normality is the ultimate outcome to target in ERA. Our study produced knowledge for designing more targeted therapeutic interventions aimed at normalizing patients' health and life in all its aspects during a crucial phase of RA.

Cited by 52 publications

References 41 publications

Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial

Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial

Incorporating the patient's perspective in outcomes research

Developing new therapeutic approaches for rheumatoid arthritis: the continuing challenges of clinical assessments

Contact Info

Product

Resources

About